Related Experiment Video
Updated: Jan 29, 2026
08:45
Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors
Published on: July 17, 2020
6.6K
Treating to Target(s) With Interleukin-17 Inhibitors
Charles W Lynde1,2,3, Jennifer Beecker4,5,6, Jan Dutz7,8
11 University of Toronto, ON, Canada.
Journal of Cutaneous Medicine and Surgery
|February 12, 2019
Summary
The treat-to-target strategy effectively guides the use of interleukin-17 (IL-17) inhibitors for autoimmune conditions like psoriasis and psoriatic arthritis. These advanced biologics demonstrate significant efficacy and safety in clinical trials.
Area of Science:
- Rheumatology and Dermatology
- Autoimmune Inflammatory Conditions
Background:
- The treat-to-target (T2T) strategy optimizes therapeutic decision-making in various medical fields.
- Interleukin-17 (IL-17) inhibitors are emerging as effective treatments for autoimmune diseases including plaque psoriasis, psoriatic arthritis (PsA), and ankylosing spondylitis (AS).
Framework:
- This article evaluates the effectiveness and safety of IL-17 inhibitors using a T2T approach for managing plaque psoriasis, PsA, and AS.
- T2T targets for these conditions were identified through a comprehensive literature search and expert meeting.
Implementation:
- Clinical trial data for secukinumab, ixekizumab, and brodalumab were assessed against established T2T safety and efficacy targets.
- The evaluation focused on achieving specific treatment goals for psoriasis, PsA, and AS.
Implications:
- IL-17 inhibitors (secukinumab, ixekizumab, brodalumab) significantly outperformed placebo and controls in meeting T2T targets for psoriasis, PsA, and AS.
- These biologics showed favorable safety profiles with low rates of serious adverse events and comorbid condition exacerbations.
- Phase III trial results confirm the T2T benefits and safety of IL-17 inhibitors for their approved indications.
Related Concept Videos
01:52Eukaryotic Transcription Inhibitors
11.0K
Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
11.0K
01:23Dipeptidyl Peptidase 4 Inhibitors
662
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
662
01:25Antihypertensive Drugs: Direct Renin Inhibitors
1.5K
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.5K
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
2.5K
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
2.5K
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
596
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
596
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
574
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
574